We tested good manufacturing practice (GMP)-manufactured CD22.BB.z-CAR T cell products (n = 5) from patients with relapsed/refractory LBCL or B-ALL enrolled on an ongoing clinical trial (NCT04088890) against N6-double knockout and N6-CD22. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.